Adicet Bio Stock Performance
| ACET Stock | USD 0.77 0.01 1.28% |
On a scale of 0 to 100, Adicet Bio holds a performance score of 6. The firm shows a Beta (market volatility) of -0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Adicet Bio are expected to decrease at a much lower rate. During the bear market, Adicet Bio is likely to outperform the market. Please check Adicet Bio's total risk alpha and the relationship between the potential upside and day typical price , to make a quick decision on whether Adicet Bio's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Adicet Bio are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating technical and fundamental indicators, Adicet Bio unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 159.7 M | |
| Total Cashflows From Investing Activities | -119.2 M |
Adicet Bio Relative Risk vs. Return Landscape
If you would invest 62.00 in Adicet Bio on April 27, 2025 and sell it today you would earn a total of 15.20 from holding Adicet Bio or generate 24.52% return on investment over 90 days. Adicet Bio is currently generating 0.5809% in daily expected returns and assumes 7.0282% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Adicet, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adicet Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adicet Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adicet Bio, and traders can use it to determine the average amount a Adicet Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0827
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ACET | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.03 actual daily | 62 62% of assets are less volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Adicet Bio is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adicet Bio by adding it to a well-diversified portfolio.
Adicet Bio Fundamentals Growth
Adicet Stock prices reflect investors' perceptions of the future prospects and financial health of Adicet Bio, and Adicet Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adicet Stock performance.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (66.67 M) | ||||
| Shares Outstanding | 82.71 M | ||||
| Price To Earning | 36.84 X | ||||
| Price To Book | 0.42 X | ||||
| Price To Sales | 9.72 X | ||||
| EBITDA | (110.65 M) | ||||
| Cash And Equivalents | 260.64 M | ||||
| Cash Per Share | 6.11 X | ||||
| Total Debt | 17.23 M | ||||
| Debt To Equity | 0.08 % | ||||
| Book Value Per Share | 1.95 X | ||||
| Cash Flow From Operations | (92.38 M) | ||||
| Earnings Per Share | (1.29) X | ||||
| Total Asset | 220.22 M | ||||
| Retained Earnings | (497.89 M) | ||||
| Current Asset | 352.66 M | ||||
| Current Liabilities | 98.91 M | ||||
About Adicet Bio Performance
Assessing Adicet Bio's fundamental ratios provides investors with valuable insights into Adicet Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Adicet Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people.Things to note about Adicet Bio performance evaluation
Checking the ongoing alerts about Adicet Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adicet Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adicet Bio is way too risky over 90 days horizon | |
| Adicet Bio has some characteristics of a very speculative penny stock | |
| Adicet Bio appears to be risky and price may revert if volatility continues | |
| Adicet Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (117.12 M) with profit before overhead, payroll, taxes, and interest of 24.99 M. | |
| Adicet Bio currently holds about 260.64 M in cash with (92.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Adicet Bio has a poor financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Adicet Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adicet Bio's stock is overvalued or undervalued compared to its peers.
- Examining Adicet Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adicet Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adicet Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adicet Bio's stock. These opinions can provide insight into Adicet Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.